 First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9 to 116 million Clinical Services revenue increased 4 to 96 million Pharma Services revenue increased 46 to 19 million Completed the acquisition of Trapelo Health in April FORT MYERS, FL ACCESSWIRE May 5, 2021 NeoGenomics, Inc. NASDAQ:NEO the Company, a leading provider of cancer-focused genetics testing services, today announced its first-quarter results for the period ended March 31, 2021. Mark W. Mallon, the Companys CEO said I couldnt be more excited to be joining NeoGenomics at such a pivotal time in the Companys history. 